Dendritic polyguanidilyated translocators for ocular drug delivery

Drug Delivery Technology

Volumn 9, Issue 9, 2009, Pages 36-43

  Durairaj, Chandrasekar ^a   Kompella, Uday B ^a,b,c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b AAPS Books Advisory Group

^c Visionary Therapeutics Corporation   (United States)

^d Appian Labs LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; CARBOPLATIN; DENDRIMER; DENDRITIC POLYGUANIDILYATED TRANSLOCATOR; GATIFLOXACIN; KETOROLAC TROMETAMOL; NANOPARTICLE; POLYAMIDOAMINE; POLYETHYLENEIMINE; TROPICAMIDE; UNCLASSIFIED DRUG;

ANTERIOR EYE SEGMENT; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IONIC STRENGTH; MACROMOLECULE; MEMBRANE TRANSPORT; NONHUMAN; PERMEABILITY BARRIER; RETINOBLASTOMA; REVIEW; SOLUBILIZATION; SYNTHESIS;

EID: 70350704816     PISSN: 15372898     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (21)

1. Najlah M, D'Emanuele A. Crossing cellular barriers using dendrimer nanotechnologies. Curr Opin Pharmacol. 2006;6:522-527. (Pubitemid 44340663)
2. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev. 2005;57:2147-2162.
3. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV. Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. J Biomed Mater Res A. 2007;82:92-103. (Pubitemid 46906494)
4. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 2007;28:504-512. (Pubitemid 44602223)
5. Chung HH, Harms G, Seong CM, et al. Dendritic oligoguanidines as intracellular translocators. Biopolymers 2004;76:83-96.
6. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol 2002;47 Suppl 1:S41-52.
7. Hamalainen KM, Kananen K, Auriola S, Kontturi K, Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci. 1997;38:627-634. (Pubitemid 27143133)
8. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-1488. (Pubitemid 28559628)
9. Kompella UB. Drug delivery to the back of the eye. Arch Soc Esp Oftalmol. 2007;82:667-668;669-670.
10. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009;26:1236-1260.
11. Kim ES, Durairaj C, Kadam RS, et al. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res. 2009;26(5):1155-1161.
12. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008;49:333-341.
13. Lee SJ, Durairaj C, Laties AM, Kadam RS, Mo Y, Geroski DH, et al. Transscleral delivery of nanoparticle triamcinolone. Invest Ophthalmol Vis Sci. 2008;49:E-Abstract 4794.
14. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1:99-114. (Pubitemid 40297959)
15. Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Liu K, Grossniklaus HE. Subconjunctival nanoparticle carboplatin in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:E-Abstract 2017.
16. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47:1149-1160.
17. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol. 2003;55:1199-1206. (Pubitemid 37180005)
18. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004;21:1797-1804.
19. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44:1192-1201. (Pubitemid 36297840)
20. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009; 16(5):645-659.
21. Durairaj C, Tyagi P, Chandler J, Kompella U. A novel dendrimer formulation for enhanced solubility and delivery of gatifloxacin, ketorolac tromethamine, and tropicamide Paper presented at ARVO 2009 Annual Meeting in Fort Lauderdale, FL. Association for Research in Vision and Ophthalmology, Inc; May 3-7, 2009.